Attached files
file | filename |
---|---|
EX-99.2 - EX-99.2 - VIASPACE Inc. | exhibit2.htm |
EX-99.1 - EX-99.1 - VIASPACE Inc. | exhibit1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | November 26, 2014 |
VIASPACE Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Nevada | 333-110680 | 76-0742386 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
382 N. Lemon Ave., Ste. 364, Walnut, California | 91789 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | 626-768-3360 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On November 26, 2014, the Registrant entered into a nonbinding Letter of Intent (LOI) to acquire luxury cosmetics company, Elite Therapeutics. The Registrant and Elite Therapeutics have agreed to carefully examine the details and potential benefits of an all-stock acquisition with an anticipated closing in the first quarter of 2015.
VIASPACE Chairman, Dr. Kevin Schewe, is the founder and majority shareholder of Elite Therapeutics, a private company based in Arvada, Colorado. Elite Therapeutics was founded in 2007 as Bad Love Cosmetics Company, LLC and began doing business as Elite Therapeutics with high quality, results-driven, medical-grade cosmetics in late 2010. Elite Therapeutics has an active, full line of luxury products and associated inventory. Bad Love Cosmetics has a cutting edge line of products in development for launch in 2015 and beyond.
A copy of the Press Release announcing this is attached to this Form 8-K as Exhibit 99.1. A copy of the LOI is attached to this Form 8-K as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
Exhibit No. Description
99.1 Press Release dated December 1, 2014.
99.2 Letter of Intent dated November 26, 2014 between VIASPACE Inc. and Bad Love Cosmetics Company, LLC, DBA Elite Therapeutics.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VIASPACE Inc. | ||||
December 3, 2014 | By: |
Stephen J. Muzi
|
||
|
||||
Name: Stephen J. Muzi | ||||
Title: Chief Financial Officer |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99.1
|
Press Release dated December 1, 2014 | |
99.2
|
Letter of Intent dated November 26, 2014 between Registrant and Bad Love Cosmetics Company, LLC, DBA Elite Therapeutics |